FDA Targets Hidden Aluminum in Hospital Nutrition Drips
Published Date: 7/3/2025
Notice
Summary
The FDA just dropped new draft rules to help drug makers keep aluminum levels safe in small and bulk parenteral nutrition products. If you make or use these products, you’ll need to follow updated labeling and aluminum limits to protect patients. This update replaces last year’s draft and aims to make sure everyone knows exactly how much aluminum is safe and how to show it on labels.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
New Aluminum Calculation Guidance
The FDA's draft guidance tells drug sponsors how to calculate aluminum content so total aluminum exposure from parenteral nutrition (PN) does not exceed an acceptable threshold. This guidance applies to small volume parenteral (SVP) drug products and pharmacy bulk packages (PBPs) used in PN.
Recommended Aluminum Concentration Limits
The draft guidance provides FDA recommendations on aluminum concentration limits for SVPs packaged as single doses and SVPs packaged in pharmacy bulk packages (PBPs). Sponsors should use these recommended limits when assessing their products for parenteral nutrition use.
Labeling Placement for Aluminum Toxicity Info
The draft guidance gives FDA recommendations on where to place information about aluminum toxicity in SVP and large volume parenteral (LVP) Prescribing Information and on container and carton labeling. Sponsors and applicants should follow these recommendations when preparing or updating labeling.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-12402 — Agency Information Collection Activities: Proposed Collection; Comment Request
CMS wants your thoughts on their plan to collect info from the public and is asking for comments over the next 60 days. This helps make sure the questions they ask aren’t too much work and actually useful. If you’re someone who deals with CMS forms, this is your chance to speak up before any changes happen.
Next: 2025-12408 — Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
The FDA just got the green light from the Office of Management and Budget to keep collecting important info from businesses and the public. This means some forms and surveys will continue, helping the FDA keep food and medicine safe without extra costs or delays. If you’re involved with FDA rules, keep an eye out for these approved info requests and their deadlines!